Simulating Disease to Radically Transform Drug Discovery & Development

GNS Healthcare and Arvinas Enter into Neuroscience Drug Discovery Collaboration

Read More >

Meet us at 2022 ASCO Annual Meeting

Evaluating Triple Therapy Treatment Pathways in Chronic Obstructive Pulmonary Disease (COPD): A Machine-Learning Predictive Model

GNS Healthcare Hires Industry Veteran, Joseph F. Donahue, as Chief Business Officer

A case for AI-driven cancer clinical trials –
The efficacy arm in silico >

GNS to Develop the World’s First in silico Patient For Prostate Cancer >

GNS Healthcare and Scipher Medicine® Collaborate to Develop World’s First in silico Patient for Rheumatoid Arthritis >

Slide 1

The case for AI-driven cancer clinical trials –
The efficacy arm in silico

Read more →

Slide 2

GNS Healthcare Announces a Multi-Year Collaboration with Memorial Sloan Kettering’s Innovation Hub to Advance Precision Medicine in Oncology

Read more →

Slide 3

GNS to Develop the World’s First in silico Patient For Prostate Cancer

Read more →

Slide 3

Listen to Dr. Ravi Parikh talk about the challenges of RCT and the GNS in silico Patient solutions

Listen to more →

previous arrow
next arrow

At GNS, we reveal the hidden biological circuitry of disease to create the world’s most accurate “virtual patients” and “digital twins”. These “virtual patients” are powered by the recent explosive growth of multi-omic and clinical patient data and our patented Causal AI and Simulation technology REFS™.

Gemini Virtual Patients enable the accurate simulation of gene and protein knockdowns at the individual patient level across “virtual patient cohorts” to discover and validate novel drug targets.

Gemini Virtual Patients also enable the simulation of disease progression and progression and drug response at the individual patient level across “virtual patient cohorts” to simulate clinical trials to better select patients, and rapidly generate comparative effectiveness evidence.

Meet Gemini

Virtual Patient

Gemini – Virtual Patient is fueled by integrated multi-omic and clinical patient data in specific diseases from a rapidly growing array of world class partners and the patented causal AI and simulation technology, REFS™. These “virtual patients” link patient characteristics to drug treatments to the “revealed” complex genetic and molecular mechanisms and pathways driving clinical outcomes, enabling the world’s most accurate simulation of disease progression and drug response at an individual patient level across “virtual patient cohorts.” Gemini Virtual Patients have been launched in multiple myeloma, prostate cancer, Alzheimer, and Parkinson’s, with several more in development.

Gemini Solutions →

Collaborate with GNS to Discover and Develop
Innovative Therapeutics

Gemini Virtual Patient
Data Partners

Gemini Virtual Patient
Biopharma Partners